!! History Commons Alert, Exciting News

Context of 'March 31, 1998: Drug Company Pays Rivals Not to Market Generic Version of Drug'

This is a scalable context timeline. It contains events related to the event March 31, 1998: Drug Company Pays Rivals Not to Market Generic Version of Drug. You can narrow or broaden the context of this timeline by adjusting the zoom level. The lower the scale, the more relevant the items on average will be, while the higher the scale, the less relevant the items, on average, will be.

Abbott Laboratories, maker of the drug Hytrin, agrees to pay rival drug company Zenith Goldline Pharmaceuticals up to $42 million not to produce a generic version of Hytrin, a drug for high blood pressure and prostate enlargement. For three years Abbott, whose patent on Hytrin expired in 1995, has been fighting Zenith in court to prevent it from marketing a cheaper generic. Abbott currently earns about $500 million a year on the drug. After signing its agreement with Zenith, Abbott inks a similar deal with another rival, Geneva Pharmaceuticals, agreeing to pay that company as much as $101 million to keep its generic version of Hytrin off the market. Geneva and Abbott will abandon their agreement a year later when the federal government launches an antitrust investigation. Consumers will sue Abbott and Geneva charging that the companies’ agreement cost patients hundreds of millions dollars. [New York Times, 7/23/2000]

Entity Tags: Zenith Goldline Pharmaceuticals, Geneva Pharmaceuticals, Abbott Laboratories

Timeline Tags: US Health Care

The Haiti Democracy Project (HDP) is formally established. At its official launching, which takes place at the Brookings Institution in Washington, D.C., speakers warn that the current “crisis” in democracy in Haiti is worsening at an ever increasing pace. “… Luigi Einaudi opened the talks with dire predictions that Haiti was fast approaching a point where diplomatic means would no longer contribute to solve the crisis. According to Einaudi, those concerned about Haiti should at this time be gathering for a ‘wake.’ The rapidly deteriorating economic situation, the inability of the main protagonists to advance the negotiating process and the increasing protest demonstrations throughout the country made for a very bleak future.” US ambassador to the OAS, Roger Noriega also speaks at the ceremony. At one point, Noriega says, referring to the contested 2000 Haitian elections (see May 21, 2000), “We have to get them [The Haitian people] that opportunity as they will not participate in a farce.” [Haiti Democracy Project, 11/20/2004] Attending the event are some questionable figures including Stanley Lucas and Olivier Nadal. Lucas is said to be the point man in Haiti for the USAID-financed International Republican Institute, which is providing training and funds to anti-Aristide Haitian rebels in the Dominican Republic (see (2001-2004)). Nadal is a Miami-based Haitian businessman and the former president of the Haitian Chamber of Commerce. [Haiti Democracy Project, 11/20/2004] Nadal is implicated in a peasant massacre that occurred in the Haitian town of Piatre. In 1990, a group of peasants were killed by Nadal’s security after they squatted on unused land that he owned. [Haiti Progres, 7/21/1999; National Coalition for Haitian Rights, 4/24/2004] The prominent businessman Antoine Izmery said shortly before he was murdered that Nadal had been one of the financiers of the 1991 coup d’etat (see October 31, 1991) that ousted Aristide from office. And in 1994, the United States government froze Nadal’s assets because of his suspected involvement in the coup. [Haiti Progres, 7/21/1999] The Haiti Democracy Project is funded by the wealthy, right-wing Haitian Boulos family, which owns several companies including Pharval Pharmaceuticals, the USAID-funded Radio Vision 2000, the Delimart supermarket, and Le Matin. In February 2002, Rudolph Boulos was under investigation for his possible involvement in the assassination of Haitian journalist Jean Dominique who had been very critical of Pharval after contamination of the company’s “Afrebril and Valodon” syrups with diethyl alcohol had resulted in the deaths of 60 children. [Haiti Progres, 7/21/1999; Haiti Weekly News, 2/28/2002; Knight Ridder, 3/11/2004; Haiti Democracy Project, 11/20/2004] The project’s board of directors includes Rudolph Boulos, CEO of Pharval Laboratories; Vicki Carney of CRInternational; Prof. Henry F. Carey of Georgia State University; Timothy Carney, US ambassador to Haiti (1998-1999); Clotilde Charlot, former vice-president of the Haitian Association of Voluntary Agencies; Lionel Delatour of the Center for Free Enterprise and Democracy (CLED); Ira Lowenthal, an “Anthropologist”; Charles Manus; Orlando Marville, Chief of the OAS electoral mission to Haiti in 2000; James Morrell, the Haiti Democracy Project’s executive director; Lawrence Pezzullo, US special envoy for Haiti (1993-1994); and Ernest H. Preeg, US ambassador to Haiti (1981-1983). [Haiti Democracy Project, 3/26/2004]

Entity Tags: Luigi Einaudi, Lionel Delatour, Orlando Marville, Roger Francisco Noriega, Stanley Lucas, Vicki Carney, Timothy Carney, Lawrence Pezzullo, Rudolph Boulos, Jean-Bertrand Aristide, Olivier Nadal, James Morrell, Antoine Izmery, Charles Manus, Ernest H. Preeg, Clotilde Charlot, Henry F. Carey, Ira Lowenthal, Jean Dominique, Haiti Democracy Project

Timeline Tags: Haiti Coup

A survey of 483 physicians by GfK Market Measures finds that one-third feel drug company sales representatives are “too aggressive or pushy.” Roughly an equal percentage says that many reps are “not knowledgeable.” One general practitioner tells GfK, “It’s silly that a highly trained sales force does not know what their product is used for and they have to ask me.” According to the survey, drug companies Pfizer and Merck are considered by doctors to have the most effective marketing teams. Abbott Laboratories’ sales force is rated as the least effective. [CNN, 9/14/2005]

Entity Tags: GfK Market Measures, Merck, Abbott Laboratories, Pfizer

Timeline Tags: US Health Care

The Pharmaceutical Research and Manufacturers of America (PhRMA) acknowledges it has funded a series of television advertisements in support of legislation primarily written by Max Baucus (D-MT), chairman of the Senate Finance Committee, to reform US health care. The television ads are part of an agreement between the Obama administration, Baucus, and PhRMA in June, where the organization agreed to various givebacks and discounts designed to reduce America’s pharmaceutical spending by $80 billion over 10 years. PhRMA then set aside $150 million for advertising to support health care legislation. More progressive House Democrats such as Henry Waxman (D-CA) are pushing for stiffer drug industry givebacks than covered in the deal. PhRMA is led by Billy Tauzin, a former Republican congressman. Until recently, the organization spent some $12 million on ads by an offshoot coalition called Americans for Stable Quality Care, and aired television ads such as “Eight Ways Reform Matters to You.” PhRMA’s new ads will specifically support the Baucus bill. Many are critical of the deal, with James Love of the progressive research group Knowledge Ecology charging, “Essentially what the US got was not $80 billion, but $150 million in Obama campaign contributions.” [New York Times, 9/12/2009] Investigative reporter Matt Taibbi agrees with Love, accusing the White House of colluding with Baucus and Tauzin’s PhRMA to orchestrate a “big bribe” in exchange for the Democrats’ dropping of drug-pricing reform in the Baucus bill. Taibbi writes that in June, White House chief of staff Rahm Emanuel met with representatives from PhRMA and drug companies such as Abbott Laboratories, Merck, and Pfizer to cut their deal. Tauzer later told reporters that the White House had “blessed” a plan involving the $150 million in return for the White House’s agreement to no longer back government negotiations for bulk-rate pharmaceuticals for Medicare, and to no longer support the importation of inexpensive drugs from Canada. Taibbi writes that the White House worked with Baucus and PhRMA to undercut Waxman’s attempts to give the government the ability to negotiate lower rates for Medicare drugs. PhRMA’s ads are being aired primarily in the districts of freshmen Democrats who are expected to face tough re-election campaigns, and in the districts of conservative “Blue Dog” Democrats, who have sided with Baucus, Obama, and PhRMA to oppose the Waxman provision in favor of PhRMA’s own provision, which would ban the government from negotiating lower rates for Medicare recipients. [True/Slant, 9/14/2009]

Entity Tags: James Love, Henry A. Waxman, Americans for Stable Quality Care, Abbott Laboratories, Rahm Emanuel, Pharmaceutical Research and Manufacturers of America, Senate Finance Committee, Obama administration, Medicare, Max Baucus, Matt Taibbi, Pfizer, Merck, W.J. (“Billy”) Tauzin

Timeline Tags: US Health Care

Ordering 

Time period


Email Updates

Receive weekly email updates summarizing what contributors have added to the History Commons database

 
Donate

Developing and maintaining this site is very labor intensive. If you find it useful, please give us a hand and donate what you can.
Donate Now

Volunteer

If you would like to help us with this effort, please contact us. We need help with programming (Java, JDO, mysql, and xml), design, networking, and publicity. If you want to contribute information to this site, click the register link at the top of the page, and start contributing.
Contact Us

Creative Commons License Except where otherwise noted, the textual content of each timeline is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike